Suven Life Sciences Completes Phase-3 Patient Enrollment for Masupirdine Study

Business Updates View source PDF Explain this filing

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹371.75

prior close

₹371.85

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+1.8% vs market

Healthcare Research Analytics & Technology peers, median of 5sector+0.3%+2.1% vs sector

On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 2.1 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+2.3

15m

+2.6

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4+0.6+1.8+0.3+2.1

Next day

+1.4+1.3+0.1-0.3+1.7

+1.4+1.7-0.3-0.1+1.5

-0.5+2.2-2.7-1.2+0.8

-3.7+2.1-5.8-1.9-1.8

-3.2+1.9-5.0-2.8-0.4

-9.9-1.3-8.6-4.6-5.3

15d

-9.6+1.3-11.0+1.8-11.4

-17.8-0.8-17.0-10.5-7.4

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suven Life Sciences has completed enrollment in its global Phase-3 study of Masupirdine (SUVN-502) for treating agitation linked to Alzheimer's dementia. 424 patients were randomized against a target of 375 across USA and Europe, testing 50 mg and 100 mg doses against placebo over 12 weeks. Last patient visit is expected by end December 2026, database lock by March 2027, and topline results by May 2027. No safety concerns observed so far.

Likely market impact

Key clinical milestone completed on schedule. Positive topline results by May 2027 could be a significant value driver for this CNS-focused pharma company.